iBio (IBIO) Stock Is Dipping: It May Be A Great Buy

iBio IBIO Stock News

iBio Inc (NYSEAMERICAN: IBIO) had a rough time in the market yesterday, dipping more than 12%. Today, the stock continues to fall. Nonetheless, the declines may be creating a discounted opportunity to get in on incredible gains in the future.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Dip May Be An Opportunity

As mentioned above, iBio stock has been dipping as of late. While the declines may scare some, in my view, this is nothing more than a discounted opportunity to get in on future gains.

Before we get into why gains are likely ahead, it’s important that you understand why the stock is falling.

For those of you who haven’t been following, IBIO has been working dilligently to develop a COVID-19 vaccine. This work is being done with its partner in China, CC Pharming.

However, yesterday, Moderna issued news surrounding their COVID-19 vaccine candidate. Apparently, it is leading to neutralizing antibodies and showing incredible promise. With the early data showing promise, investors are concerned that other competitors in the race to develop a vaccine will be first to hit the market.

I’m here to tell you that doesn’t matter!

The truth of the matter is that COVID-19 is a very serious condition, as we all know. It has shut down the United States economy and other economies around the world, killed hundreds of thousands of people, and continues to spread.

As such, when a vaccine is developed, demand is expected to be incredibly high. In fact, demand around the world will likely be so high that when a vaccine is approved, there will be an immediate shortage in availability.

So, even if IBIO isn’t the first to have a vaccine approved, the opportunity in the space is incredible.

Should the company bring a vaccine candidate to market, it will be met with just as strong of demand as expected. Moreover, it might be able to actually meet that demand.

Let’s not forget, IBIO is the only company with te FastPharming Facility. The facility was developed with government funding to be able to produce vaccine candidates and other biological agents should a pandemic arise.

Well, that pandemic is here and iBio now has all the tools it needs to quickly produce mass amounts of vaccines. This is incredlby valuable.

The Bottom Line

While Moderna did release positive news, it doesn’t matter who develops the first vaccine. What matters is that vaccines are developed and can be produced quickly. iBio’s CC Pharming partnership gives it a partner that has already developed vaccines for different strains of the coronavirus. As such, there’s a high likelihood that the two companies will develop a viable vaccine for this strain.

That, combined with the ability of the FastPharming Facility to develop vaccines at an ultra-fast pace, makes IBIO stock one that you should be paying attention to.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.